Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02314026 · ClinicalTrials.gov registry record · Phase 2
BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH
A Phase 2 study, sponsored by Meridian Bioscience.
- Completed
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
NCT02314026 is a Phase 2 study that has completed, run by Meridian Bioscience. The registered enrollment target is 140 participants.
The verdict
NCT02314026, a Phase 2 study, has completed, sponsored by Meridian Bioscience.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
Study Summary
This study's aim is to develop an algorithm for the ¹³C-Octanoate Breath Test with or without the ¹³C-Methacetin Breath Test (OBT and MBT respectively) for correlation with histological findings associated with of Non-Alcoholic Steatohepatitis (NASH) and other liver diseases using the BreathID® System
Interventions
- DEVICE Suspected NASH BreathID test with 13C-Octanoate
- DEVICE Suspected NASH Breath test with 13C Methacetin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2015-03 |
| Est. Completion | 2017-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02314026
The ClinicalTrials.gov registry entry for NCT02314026 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Meridian Bioscience, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Suspected NASH BreathID test with 13C-Octanoate is the first listed.
NCT02314026 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02314026 about?
NCT02314026 is a clinical study titled "BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH". This study's aim is to develop an algorithm for the ¹³C-Octanoate Breath Test with or without the ¹³C-Methacetin Breath Test (OBT and MBT respectively) for correlation with histological findings associated with of Non-Alcoholic Steatohepatitis (NASH) and other liver diseases using the BreathID® Syst...
What is the current status of trial NCT02314026?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2015-03. Estimated completion is 2017-06.
What interventions are being tested in trial NCT02314026?
The interventions under investigation include: Suspected NASH BreathID test with 13C-Octanoate (DEVICE), Suspected NASH Breath test with 13C Methacetin (DEVICE).
Who is sponsoring clinical trial NCT02314026?
This trial is sponsored by Meridian Bioscience, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.